Investigation of Insulin Secretion in Glucose Tolerance Test by the Intake of Novel Imeglimin (Twymeeg)-Reference-Cited by-同舟云学术

Investigation of Insulin Secretion in Glucose Tolerance Test by the Intake of Novel Imeglimin (Twymeeg)

Published:2022-08-19 Issue:3 Volume:5 Page:113-119
ISSN:2582-0370
Container-title:Asploro Journal of Biomedical and Clinical Case Reports
language:en
Short-container-title:Asp Biomed Clin Case Rep

Author:

BANDO Hiroshi¹^ORCID,OGAWA Hiroko²,URASAKI Hirohisa³,NAGAHIRO Shinji⁴,URASAKI Hiroko⁵,NAKANISHI Miwako²,WATANABE Osami²

Affiliation:

1. Medical Research / Tokushima University, Tokushima, Japan; Yoshinogawa Hospital, Tokushima, Japan; Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Tokushima, Japan

2. Yoshinogawa Hospital, Tokushima, Japan

3. Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Tokushima, Japan; Nankai Hospital, Naruto city, Tokushima, Japan

4. Yoshinogawa Hospital, Tokushima, Japan; Emeritus Professor, Former Director of Tokushima University Hospital, Tokushima, Japan

5. Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Tokushima, Japan

Abstract

Background: Recent pharmacological studies reveal imeglimin (Twymeeg) including dual mechanisms for stimulating insulin secretion and reducing insulin resistance. Case Presentation: The case is a 62-year-old male with type 2 diabetes (T2D). He showed HbA1c 6.4% and started imeglimin. After 5 weeks, a 75g oral glucose tolerance test (75gOGTT) was conducted, and the biomarkers were compared with that of 6 months ago. Insulinogenic index (IGI) 0-30min was stable, but insulin secretion was increased during 30-60min and 60-120min. Discussion: Previous studies of imeglimin revealed improved insulin secretion for GTT. Clinical progress will be followed up with detailed investigation of glucose and insulin variability.

Publisher

Asploro Open Access Publications

Subject

General Medicine

Reference27 articles.

1. Gram-Kampmann EM, Hansen CD, Hugger MB, Jensen JM, Brønd JC, Hermann AP, Krag A, Olsen MH, Beck-Nielsen H, Højlund K. Effects of a 6-month, low-carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open-label randomized controlled trial. Diabetes Obes Metab. 2022 Apr;24(4):693-703. [PMID: 34984805]

2. American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee:, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S60-82. [PMID: 34964866]

3. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015 Jan;31(1):1-13. Erratum in: Nutrition. 2019 Jun;62:213. [PMID: 25287761]

4. Muneta T, Hayashi M, Nagai Y, Matsumoto M, Bando H, Ebe K, Watanabe H, Watanabe S. Ketone Bodies in the Fetus and Newborn During Gestational Diabetes and Normal Delivery. Int J Diabetes. 2022;3(1):142-48.

5. Bando H. Useful tips for actual low carbohydrate diet (LCD) with super-, standard- and petite-LCD methods. EC Nutrition. 2020;15(5):01-04

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2023-06-12